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A randomized, controlled trial comparing IV iron sucrose to
oral iron in anemic patients with nondialysis-dependent CKD.
Background. Although iron deficiency frequently compli-
cates anemia in patients with nondialysis-dependent CKD (ND-
CKD), the comparative treatment value of IV iron infusion and
oral iron supplementation has not been established.
Methods. In a randomized, controlled multicenter trial, we
compared the efficacy of iron sucrose, given as 1 g in divided IV
doses over 14 days, with that of ferrous sulfate, given 325 mg
orally thrice daily for 56 days in patients with ND-CKD stages
3 to 5, Hb ≤11 g/dL, TSAT ≤25%, and ferritin ≤300 ng/mL.
Epoetin/darbepoetin therapy, if any, was not changed for eight
weeks prior to or during the study.
Results. The proportion of patients achieving the primary out-
come (Hb increase ≥1 g/dL) was greater in the IV iron treat-
ment group than in the oral iron treatment group (44.3% vs.
28.0%, P = 0.0344), as was the mean increase in Hb by day
42 (0.7 vs. 0.4 g/dL, P = 0.0298). Compared to those in the IV
iron group, patients in the oral iron treatment group showed a
greater decline in GFR during the study (−4.40 vs. −1.45 mL/
min/1.73m2, P = 0.0100). No serious adverse drug events (ADE)
were seen in patients administered IV iron sucrose as 200 mg
IV over two to five minutes, but drug-related hypotension, in-
cluding one event considered serious, occurred in two females
weighing less than 65 kg after 500 mg doses were given over
four hours.
Conclusion. IV iron administration using 1000 mg iron su-
crose in divided doses is superior to oral iron therapy in the
management of ND-CKD patients with anemia and low iron
indices.
Iron deficiency afflicts anemic patients at all stages of
chronic kidney disease (CKD). Only among patients with
hemodialysis-dependent CKD (HD-CKD), however, is
evidence both reliable and sufficient to guide iron ther-
apy. In HD-CKD, efficacy favors intravenous (IV) iron
over oral iron supplements [1], safety favors use of IV
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iron sucrose or ferric gluconate over iron dextran at doses
ranging from 25 to 125 mg [2], and diagnostic utility fa-
vors the iron status tests transferrin saturation (TSAT),
ferritin, and content of hemoglobin in reticulocytes (CHr)
[1, 2].
Among patients with nondialysis-dependent CKD
(ND-CKD), by contrast, evidence on key issues of iron
efficacy, safety, and test utility is missing, sparse, or incon-
clusive. For example, three randomized, controlled trials
(RCTs) comparing efficacy of IV iron to oral iron in ane-
mia of ND-CKD have yielded contradictory results. The
first showed that IV iron is not superior to oral iron [3].
The second showed that IV iron is superior to oral iron
in raising Hb >11 g/dL but not in raising Hb > 1 g/dL.[4].
The third showed that IV iron is unequivocally superior
to oral iron [5].
Currently, the highest FDA-approved single dose for
iron dextran and iron sucrose is 100 mg, and for fer-
ric gluconate, 125 mg. Administration of higher doses
in ND-CKD patients offers the potential to spare time,
venous access, and the burden of added pills. Iron dex-
tran, which has been given IV at doses of 500 to 1000 mg
and greater, poses the risk of anaphylaxis [6]. Ferric glu-
conate has been given IV up to 125 mg over 10 minutes
and up to 250 mg infused over 60 minutes, but adminis-
tration at higher doses and infusion rates raises the risk
of hypotension and other labile iron-mediated adverse
effects [6]. Iron sucrose is FDA-approved at doses of
200 mg and has been administered at doses of 200 mg
over five minutes and has been administered at 500 mg
over three to four hours, but additional prospective stud-
ies are needed examining these doses in large numbers of
patients.
In anemic patients with ND-CKD, low iron indices are
common. TSAT levels below 20% and ferritin levels be-
low 100 ng/mL are seen in as many as 20% to 70% of
patients, depending on CKD stage and gender [7]. How-
ever, little is known about the relationship between base-
line levels of iron status tests and likelihood of response
to an IV iron challenge.
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Fig. 1. Study design, depicting enrollment, and randomization to either IV iron treatment or oral iron treatment. Subjects not immediately eligible
upon enrollment were followed for up to 10 weeks and randomized if they became eligible.
Iron therapy in HD-CKD patients serves as an
adjuvant to erythropoiesis-stimulating agents (ESAs),
including epoetin alfa, epoetin beta, or darbepoetin. By
contrast, in patients with ND-CKD, only a third of pa-
tients receive ESA therapy [8]. Iron therapy in these
patients may be undertaken as primary treatment of ane-
mia. The important benefits of treating anemia in CKD,
the cost of ESA therapy, the potential for iron therapy
to lower or eliminate ESA doses, and the possibility that
concurrent ESA therapy exerts a differential effect on ef-
ficacy of IV and oral iron agents, all emphasize the need
for detailed comparative information on iron efficacy in
ND-CKD patients.
Accordingly, we conducted an RCT comparing IV iron
sucrose to oral ferrous sulfate in anemic ND-CKD pa-
tients. We included patients with and without concurrent
ESA therapy. We compared the efficacy of IV to oral iron,
assessed the safety of iron sucrose given at 200 mg and 500
mg doses, and evaluated the relationship between base-
line iron indices and likelihood of response to IV iron
challenge.
METHODS
Study design
This was an open-label, Phase III, randomized, active-
controlled, multicenter trial. Anemic patients with stage
3 to 5 ND-CKD who required iron supplementation,
met all inclusion and exclusion criteria, and had given
informed consent were enrolled into the study at 35
study sites. We randomized patients into the study if they
met the following criteria: hemoglobin (Hb) ≤11.0 g/dL,
TSAT ≤25%, ferritin ≤300 ng/mL, either no ESA or no
ESA dose change for eight weeks, and no parenteral iron
for six months. We permitted oral iron use prior to en-
rollment. Subjects who were not immediately eligible for
randomization underwent monthly laboratory examina-
tion for up to 10 weeks, followed by randomization upon
meeting eligibility criteria (Fig. 1).
At randomization, patients were assigned to one of two
treatment groups. Patients in the IV iron treatment arm
received intravenous iron sucrose (Venofer; American
Regent, Inc., Shirley, NY, USA) 1000 mg in divided doses
over 14 days, as either 500 mg IV infusions on study days
0 and 14 or 200 mg injections on five different days from
day 0 to day 14. Patients in the oral iron treatment arm
received oral ferrous sulfate (CVS Corp., Woonsocket,
RI, USA; Geri-Care Pharmaceuticals Corp., Brooklyn,
NY, USA), 325 mg thrice daily, providing 195 mg ferrous
iron per day, for 56 days. Clinical laboratory evaluation
and safety assessment was performed every two weeks
through day 56, and results were compared to baseline
values.
Inclusion criteria for enrollment
Patients were eligible for enrollment if they were over
the age of 18, able to give informed consent, and evi-
denced both anemia (Hb ≤11.5 g/dL) and chronic kidney
disease stage 3 to 5.
Exclusion criteria for enrollment
Patients were excluded for enrollment if they had a
history of known sensitivity to any component of ferrous
sulfate or iron sucrose; chronic or serious infection, malig-
nancy, or major surgery in the month prior to enrollment;
parenteral iron within six months prior to enrollment;
blood transfusion within the two months prior to enroll-
ment; clinically significant bleeding within three months
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prior to enrollment; concomitant severe diseases of the
liver, cardiovascular system, severe psychiatric disorders,
or other conditions which, in the opinion of the investiga-
tor, made participation unacceptable; pregnancy or lac-
tation; current treatment for asthma; anticipated surgery
requiring hospitalization during the study period other
than vascular access or peritoneal catheter placement;
anticipated dialysis or renal transplantation during the
study; administration of an investigational drug within
30 days of enrollment; chronic alcoholism or drug abuse
within the past six months; and known hemochromato-
sis or hemosiderosis. We examined stool for heme prior
to randomization; subjects with positive results required
investigator assessment and approval to be randomized.
Criteria for randomization
Patients were eligible for randomization if they con-
tinued to meet the enrollment criteria and met the fol-
lowing additional criteria: Hb ≤11.0 g/dL, based on the
average of two results obtained on different days within
a seven-day period and differing by ≤0.5 g/dL; TSAT
≤25%; ferritin ≤300 ng/mL; stable (no dose change) or
no erythropoietin use × eight weeks; and no iron therapy
following enrollment.
Criteria for premature withdrawal
Premature withdrawal was required if renal replace-
ment therapy (dialysis or transplantation) was initiated
or an intervention for management of anemia was given.
We defined an anemia intervention as either a red blood
cell transfusion, an increase in epoetin or darbepoetin
dose, or iron administration not included in the study pro-
tocol. Of course, subjects who wished to withdraw from
the study could do so at any time without the need to
justify the decision, and investigators could withdraw a
subject at any time if withdrawal was felt to be in the
best interest of the subject. In the analysis of efficacy and
safety, we included data for each patient up to the time
of withdrawal.
Treatment
IV iron treatment arm patients received iron sucrose
1000 mg IV in divided doses over a 14-day period as either
a 500 mg infusion in 250 mL 0.9% NaCl given over 3.5
to 4 hours on days 0 and 14 (approximately 2 mg/min),
or a 200 mg injection undiluted over two to five minutes
(approximately 40 mg/min) on five different occasions
within the 14-day period beginning on day 0.
Oral iron treatment arm patients received ferrous sul-
fate as 325 mg tablets (65 mg elemental iron) with instruc-
tions to take one tablet by mouth (PO) three times daily
(t.i.d.) with eight ounces of tap water one hour before
meals from day 0 until day 56.
Randomization method for assigning treatment group.
We first identified subjects as ESA-treated or non–ESA-
treated. We then independently stratified ESA-treated
and non–ESA-treated subjects by gender and Hb level
(≤9.0 g/dL, 9.1 to 10.0 g/dL, and 10.1 to 11.0 g/dL). Within
each resulting combination of strata, we then randomized
subjects in a 1:1 ratio to study iron treatment groups A
and B.
Determination of efficacy and safety
Efficacy. The primary measure of efficacy was an in-
crease in Hb of at least 1.0 g/dL at any time between
baseline and either the end of study or withdrawal. We
determined sample size for this study based on the hy-
pothesis that the response rate with a 1.0 g/dL increase
in Hb over pretreatment levels was 40% in the iron su-
crose arm and 15% in the oral iron arm. A minimum of
72 subjects was required in each arm to assess such a dif-
ference in response by means of Fisher exact test with a
two-sided significance level of 0.05 and a power of 0.90.
We assumed that 10% of subjects enrolled in the obser-
vation phase would not meet criteria for randomization.
Thus, we aimed to enroll approximately 160 subjects.
Secondary end points included the observed increase
in Hb, TSAT, ferritin, and CHr after treatment.
We determined adherence to prescribed treatment
with IV iron by recording time and date of each iron
sucrose infusion or injection. We determined adherence
with prescribed oral iron therapy by counting pills taken
from blister packs distributed and returned at two-week
intervals. To calculate adherence rate, we divided the
number of doses so counted for each study patient by
the number of doses prescribed during the period of the
patient’s study participation.
We assessed quality of life using normalized data from
the SF-36 instrument, version 1 [9].
Laboratory evaluation. Blood samples for laboratory
analyses obtained at all appropriate visits were analyzed
by a central laboratory. We determined the full panel of
hematologic indices, iron indices, and C-reactive protein
at enrollment and days 14, 28, 42, and 56 after initiating
therapy. We determined the baseline Hb as the average of
the two most recent Hb values taken one week apart prior
to randomization. We determined routine clinical chem-
istry at enrollment and at day 56. Iron indices included
serum iron, total iron binding capacity, transferrin satura-
tion, and ferritin, and content of reticulocyte Hb (CHr).
We predicted GFR by the MDRD formula [10].
Safety (adverse events). We monitored blood pressure
and recorded adverse events in all patients before, during,
and after administration of IV iron. We asked all subjects
to report any untoward medical event at their onset and
were queried also at each study visit. We recorded adverse
events from the day of consent through the completion
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of the study (day 56) or 30 days following the last dose of
study drug, whichever was later. Investigators provided
the date of onset, severity, the relationship to study drug,
the date of resolution (or the fact that the event was still
continuing), the action taken, and the outcome of the
adverse experience.
We did not consider worsening anemia or iron defi-
ciency to be adverse events because these developments
became study end points if an anemia intervention was
required, as defined above.
We classified potential hypersensitivity reactions by
grade as events occurring from the start of drug infusion
to 20 minutes after the completion of the infusion, ac-
cording to accepted guidelines (National Cancer Institute
Common Terminology for Adverse Events, version 2.0;
NCITEPHELP@ctep.nci.nih.gov). Investigators graded
events that lacked accepted terminology as mild (did not
interfere with subject’s usual function), moderate (inter-
fered to some extent), severe (interfered significantly), or
life-threatening (resulted in a threat to life or an incapac-
itating disability). A serious adverse event included any
experience that was fatal or life-threatening, resulted in
or prolonged inpatient hospitalization, resulted in persis-
tent or significant disability or incapacity, or presented
a significant hazard to the subject. Investigators judged
relationship to study drug as none, unlikely, possible, or
probable.
Statistical analysis
Primary efficacy end point. The principal analysis
of the primary end point was the unstratified compar-
ison of the Hb response rate between the two study
arms (IV iron sucrose versus oral iron) in the combined
non-erythropoietin and erythropoietin-treated popula-
tion, using a two-sided Fisher exact test at the 0.05 signif-
icance level. Analysis of response by visit was evaluated
using the Cochran-Mantel-Haenszel (CMH) test control-
ling for center (not stratified by other factors). The null
hypothesis of no difference between the treatment groups
in proportion of Hb responders was rejected if the P value
of association was ≤ 0.05. We used a logistic regression
model to evaluate the effect of potential covariates on
the odds of achieving the 1.0 g/dL Hb response at the
day 56 visit based on the last observation carried forward
method.
Secondary efficacy end points. We compared sec-
ondary responses for subjects in the two study arms using
a two-sided Fisher exact test at the 0.05 significance level.
We examined all time-dependent efficacy end points, in-
cluding anemia intervention, using Kaplan-Meier sur-
vival curves. This method estimated the median and 95%
confidence limits for the time-to-event in each treatment
group. We compared iron sucrose to oral iron using a Cox
proportional hazard model with effects for treatment,
baseline Hb, and any demographic characteristics that
were found to be statistically significantly different be-
tween treatment groups. We analyzed change from base-
line in Hb, ferritin, TSAT, and normalized SF-36 quality
of life results for each treatment group at each study visit
during the study using a pair-sample t test and an analysis
of covariance (ANCOVA) model.
RESULTS
Patient disposition
One hundred eighty-eight (188) subjects were random-
ized at 35 centers to receive iron sucrose (95 subjects) or
oral iron (93 subjects). Of these 188 subjects, four were
randomized to iron sucrose and two were randomized
to oral iron, but were discontinued from the study prior
to dosing (Fig. 2). Of these six patients, two were lost to
follow-up, three were withdrawn due to subject request,
and one received a blood transfusion. All six subjects
were excluded from the evaluation of both safety and
efficacy. Therefore, the safety evaluable population in-
cluded a total of 182 subjects who received at least one
dose of iron: 91 subjects in the iron sucrose group and 91 in
the oral iron group. The intent to treat population, which
formed the basis for efficacy analysis, included all safety
evaluable subjects who had efficacy data after baseline,
except for eight patients in each group who were found to
have been randomized despite ESA dose changes within
eight weeks prior to randomization. Twelve patients (5 in
the IV iron group and 7 in the oral iron group; P = NS)
required anemia intervention.
Efficacy
Among patients in the intent-to-treat population, there
were no significant differences at baseline between pa-
tients in the IV iron group and those in the oral iron
group in demographic descriptors, iron status, or severity
of anemia (Table 1).
Adherence to prescribed therapy. Mean adherence was
greater among patients in the IV iron treatment group
(mean and 95% CI 97.3, 94–3–100.0) compared to those
in the oral iron treatment group (88.5, 84.8–92.3). The
proportion of patients showing adherence at or above the
80% threshold was also higher in the IV iron treatment
group (96.2%) compared to the oral iron treatment group
(76.8%).
Hemoglobin response. In the IV iron group compared
to the oral iron group, the proportion of patients who
achieved the primary end point, a rise in Hb ≥1.0 g/dL,
was greater (44.3% vs. 28.0%, P = 0.0344) and the mean
increase in Hb was higher by day 42 (0.7 vs 0.4 g/dL, P =
0.0298; Fig. 3).
Factors associated with superior IV iron efficacy com-
pared to oral iron efficacy included baseline ferritin
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Fig. 2. Disposition of study patients after screening. We examined safety in the safety evaluable population and efficacy in the intent-to-treat
population.
>100 ng/mL, baseline Hb ≥10 g/dL, GFR ≤45 mL/min,
use of ESA with Hb ≥10 g/dL, non-use of ESA with GFR
≤45 mL/min, age ≥65 years, and male gender (Table 2).
Use of ESA was associated with a higher proportion of
patients achieving the primary end point in both the IV
iron group (ESA use vs. non-use: 53.1% vs. 38.3%) and
the oral iron group (32.2% vs. 25.5%), but this finding did
not reach statistical significance.
Patients in the IV iron treatment group were more
likely to achieve a minimum KDOQI-recommended Hb
level (≥11 g/dL) than were those in the oral iron treat-
ment group [47/79 (59.5%) vs. 35/81 (43.2%); P = 0.0165].
The proportion of patients achieving Hb ≥11 g/dL was
unaffected by use or non-use of ESA (positive response,
ESA use vs. no ESA use: 60.0% vs. 59.4%, IV iron treat-
ment group; 45.2% vs. 41.2%, oral iron treatment group).
Iron stores and iron adequacy for erythropoiesis, re-
sponse to treatment. Serum ferritin increased signifi-
cantly from baseline in both treatment groups, but the
rise in ferritin was much greater among patients in the
IV iron group than among those in the oral iron group
(Fig. 4). TSAT increased in both groups. Differences be-
tween groups narrowly failed to achieve statistical signif-
icance (e.g., P = 0.071 at 42 days, P = 0.055 at 56 days).
IV iron treated patients showed significant increases in
content of Hb in reticulocytes (CHr) at every study in-
terval. Oral iron treated patients showed significant CHr
increases only at days 28 and 42. Between-group differ-
ences in CHr, however, were not statistically significant
at any interval.
Table 1. Baseline demographic and laboratory values among
intent-to-treat patients in IV iron and oral iron treatment groups
Treatment group
IV iron Oral iron
Baseline results (N = 79) (N = 82) P value
Demographics
Age years 62.3 63.9 0.2340
Race Caucasian/black/other 44/30/5 40/38/4 0.5575
Gender Male/Female 26/53 26/56 1.0000
Epoetin or darbepoetin 32/47 31/51 0.7490
User/Nonuser
Weight kg 85.6 83.4 0.3065
Laboratory
Hb g/dL 10.2 10.1 0.5516
TSAT% 16.4 16.7 0.9193
Ferritin ng/mL 92.6 103.8 0.9393
TSAT <20% and Ferritin 30 33 0.8718
<100 ng/mL N
Estimated GFR mL/min/1.73 m2 30.4 28.5 0.8256
Clinical utility of baseline iron indices. We assessed
the clinical utility of baseline iron status tests to predict
response to IV iron therapy (≥1 g/dL increase). For each
test, we created a receiver operating characteristic (ROC)
curve by plotting the percent of responding subjects who
were correctly identified by the test against the percent
of nonresponding subjects who were falsely identified as
responders by the test (Fig. 5). A perfect test would have
been represented on the graph as point (0, 1) in the upper
left corner because 100% of responding subjects would
have been correctly identified and 0% of nonresponding
subjects would have been falsely identified as responders.
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Fig. 3. Hemoglobin response in anemic CKD patients after IV iron
compared to oral iron therapy. Proportion of patients achieving pri-
mary end point (Hb ≥1.0 g/dL), upper panel; and actual Hb, lower
panel (mean ± 95% CI of mean). Between treatment groups, signifi-
cant differences were present by day 42 (P < 0.05). Within each group,
significant differences from baseline are shown (∗P < 0.05; ∗∗<0.01,
∗∗∗<0.001).
An uninformative, random test would produce a diago-
nal line from the origin (0, 0) to the upper right corner
of the graph (1, 1). Useful tests produce curves substan-
tially above this diagonal line. Baseline TSAT, ferritin,
and CHr are poor predictors of response to IV iron ther-
apy, as illustrated by their curves in Figure 5. All curves
but one are near the diagonal line representing uninfor-
mative random results, and the remaining test has a curve
suggestive of worse than random predictive ability. The
relationship between baseline iron tests and response to
IV iron therapy was also weak (Fig. 6).
Quality of life. We found no statistically significant
differences between the treatment groups for the mean
change from baseline to day 56 in the health concept
categories of physical functioning, role-physical, bod-
ily pain, general health, vitality, social functioning, role-
emotional, and mental health.
Safety
Extent of exposure. The mean cumulative per patient
dose of IV iron administered was 973.4 mg (95% CI of the
mean 943.1–1003.7 mg) and the mean cumulative dose of
oral iron was 9031.0 mg (8446.5–9615.6). Sixty-one pa-
tients received 280 doses of iron sucrose as 200 mg over
two to five minutes, and 30 patients received 58 doses of
iron sucrose as 500 mg over 3.5 to 4 hours.
Table 2. Baseline value or condition associated with differential
primary end point response to IV compared to oral iron (Hb
≥1.0 g/dL)
Baseline value IV iron Oral iron IV vs. oral
or condition N/total% N/total% P valuea
Overall 35/79 (44.3%) 23/82 (28.0%) 0.0344
Ferritin
<100 ng/mL 21/49 (42.9%) 16/46 (34.8%) 0.4199
≥100 ng/mL 14/30 (46.7%) 7/36 (19.4%) 0.0181
Hb
>10 g/dL 23/55 (41.8%) 17/56 (30.4%) 0.2086
≤10 g/dL 12/24 (50.0%) 6/26 (23.1%) 0.0475
GFR
>45 mL/min/1.73m2 5/12 (41.7%) 8/12 (66.7%) 0.2191
≤45 mL/min/1.73m2 30/67 (44.8%) 15/70 (21.4%) 0.0036
ESA use and GFR ≤45 mL/min/1.73m2
No ESA use 16/40 (40.0%) 6/40 (15.0%) 0.0123
ESA use 14/27 (51.9%) 9/30 (30.0%) 0.0931
ESA use and baseline Hb ≤10 g/dL
No ESA use 4/13 (30.8%) 4/16 (25.0%) 0.7296
ESA use 8/11 (72.7%) 2/10 (20.0%) 0.0157
Age years
<65 15/41 (36.6%) 13/39 (33.3%) 0.7605
≥65 20/38 (52.6%) 10/43 (23.3%) 0.006
Gender
Male 13/26 (50.0%) 4/26 (15.4%) 0.0078
Female 22/53 (41.5%) 19/56 (33.9%) 0.4141
aP value estimated from two-sided Fisher exact test or, within a subgroup,
using a Pearson’s chi-square test.
Adverse events. Seventy subjects in the iron sucrose
group and 72 in the oral iron group completed the study.
Eight subjects in each group required anemia interven-
tion and did not complete the study. An additional 24 sub-
jects (13 iron sucrose, 11 oral iron) discontinued for
reasons other than intervention (Table 3). Of the four
in the iron sucrose group who discontinued due to ad-
verse events, three experienced adverse events that were
considered study drug-related. Two of the three expe-
rienced symptomatic hypotension that resolved sponta-
neously after or near the end of a four-hour 500 mg iron
infusion. The first, a 73-year-old female weighing 46.7 kg,
received 500 mg IV iron (10.7 mg/kg) over 240 min-
utes, evidenced a blood pressure of 140/61 mm Hg after
completion of the infusion, but experienced hypotension
(60/40) 25 minutes later. She was transported to an emer-
gency department, where her blood pressure was found
to have risen to 143/64 mm Hg without treatment. She was
observed without further treatment and released. The in-
vestigator recorded the hypotension as nonserious, grade
3, probably related to study drug. The second, a 67-year-
old female weighing 62.5 kg, experienced hypotension
(80/60) in association with dyspnea, and a burning sensa-
tion in the chest after receiving 480 mg (7.7 mg/kg) of a
planned 500 mg infusion, three hours and 50 minutes after
initiating the infusion. She was transported to an emer-
gency department, where her blood pressure was found
to have risen to 145/65. She felt “90% better.” She was ad-
ministered IV solumedrol and released. The investigator
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Fig. 4. Change in iron status indicators in patients after IV iron com-
pared to oral iron therapy (mean ± 95% CI of mean). Between-group
differences were significant for ferritin (P < 0.0001) and TSAT (P =
0.0411), but not CHr (P = 0.1613). Within each group, significant dif-
ferences from baseline are shown (∗P < 0.05; ∗∗<0.01, ∗∗∗< 0.001).
recorded the event as serious, grade 3, probably related to
study drug (serious ADE). The third patient experienced
nausea the day after his first 200 mg dose of IV iron su-
crose. Symptoms progressed over the next two weeks to
include cough; he asked to be discontinued from study,
and on exit physical exam on study day 15 he was found
to be febrile. Left lower lobe pneumonia was confirmed,
he was treated with IV antibiotics, and he recovered. The
investigator recorded the nausea as nonserious, grade 1,
unlikely to be related to study drug, and the pneumonia
as grade 3, unrelated to study drug. Finally, one additional
patient in the IV iron group and two in the oral iron group
withdrew due to adverse events unrelated to study drug
(pneumonia, hip fracture, and hip fracture, respectively).
No serious ADE were seen in patients receiving 200 mg
doses of IV iron sucrose or oral iron (Table 4). There were
no deaths in either study group during the trial.
During the study, 22% (20/91) of the subjects in the IV
iron group and 19% (17/91) of the subjects in the oral iron
group reported at least one nonserious ADE. Among
nonserious ADE reported, GI complaints were seen most
frequently in both treatment groups, but the nature of GI
complaints differed between groups (Table 5). Transient
taste disturbance (dysgeusia) was the most prominent GI
complaint associated with IV iron administration. Con-
stipation, diarrhea, nausea, vomiting, and dyspepsia were
associated prominently with oral iron therapy. Headache,
myalgia, and hypotension (as described above) were ex-
clusively associated with IV iron administration.
Laboratory evaluation. There were no significant
changes in clinical biochemistry laboratory results at any
interval except for estimated GFR. Among patients who
completed the study, we found a decline in GFR from
baseline in both treatment groups (GFR in IV iron
group: −1.45 mL/min/1.73m2, 95% CI −0.2 to −2.67, P =
0.0208; oral iron group −4.40, 95% CI −2.5 to −6.29, P <
0.0001). Loss of GFR was greater among patients in the
oral iron group than among those in the IV iron group
(P = 0.0100).
DISCUSSION
We report the results of a prospective, randomized,
controlled trial of IV iron therapy compared to oral iron
therapy in patients with ND-CKD, anemia, and evidence
of iron deficiency. Our results show that IV iron is su-
perior to oral iron in replenishing iron stores, improving
adequacy of iron for erythropoiesis, raising the mean Hb
to above 11 g/dL, and achieving the primary therapeutic
end point, a Hb rise of ≥1 g/dL from baseline.
Differences in experimental design probably explain
differences between our findings and those of two pre-
vious RCTs comparing IV iron to oral iron therapy in
ND-CKD. The first study found no difference between
the effects of IV iron compared to oral iron therapy on
the rise in Hb after initiating ESA therapy [3]. That trial
was designed and powered as a nonsuperiority trial. Com-
pared to the current trial, the previous trial enrolled few
patients using ESA therapy prior to enrollment (N =
2), the total study population was much smaller (N = 45
randomized, 32 completed), the initial IV iron doses were
smaller (300 mg) and were repeated monthly (6 months),
and ESA therapy was not fixed but rather was initiated
in all study patients at a sizeable dose (2000 U epoetin
alfa subcutaneously twice weekly) simultaneous with iron
therapy. Although TSAT was not measured, the base-
line median percent hypochromic red cells (PHRBC) was
normal in both groups, suggesting that iron was adequate
for erythropoiesis at baseline. Small sample size, small
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Fig. 5. Receiver operating characteristic
(ROC) curves, examining the utility of iron
status tests to distinguish iron deficient from
nondeficient study patients. We defined true
iron deficiency as a Hb ≥1 g/dL after IV
iron treatment. The utility of all tests, alone or
in combination, was poor at each cutoff value
examined. Results are shown for patients in
the IV iron treatment group, with or without
ESA therapy.
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Fig. 6. Relationship between baseline iron status and response to IV iron as evidenced by either peak increase in the content of hemoglobin in
reticulocytes (∆CHr) or peak increase in total circulating Hb (∆Hb). Results are shown for patients in the IV iron treatment group, with or without
ESA therapy.
doses of IV iron given over a long period of time, initi-
ation of ESA in previously untreated patients, and iron
sufficiency at baseline all tend to minimize the discernable
effects of iron treatment and, therefore, favor nonsupe-
riority of IV compared to oral iron.
A second RCT compared IV to oral iron therapy in
ND-CKD patients [4]. Patients receiving IV iron showed
a greater increase in Hb than those receiving oral iron,
but differences in the primary outcome, the proportion of
patients with a Hb rise ≥1.0 g/dL, did not reach statistical
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Table 3. Reasons for discontinuation other than anemia intervention,
by treatment group
IV iron Oral iron
Reasons for discontinuation group group
Adverse event related to study drug 3 (3.3%) 0
Adverse event unrelated to study drug 1 (1.1%) 2 (2.2%)
Required hemodialysis 3 (3.3%) 3 (3.3%)
Selection criteria/study compliance 2 (2.2%) 0
Lost to follow-up 0 2 (2.2%)
Subject request unrelated to adverse event 4 (4.4%) 2 (2.2%)
Other 0 2 (2.2%)
Results shown as numbers of patients (% of group total). Each reason is
unique to each patient: no patient is listed more than once.
Table 4. Serious adverse drug events (ADE) after IV iron by dose
size, in safety evaluable patients
Serious ADE incidenceDose size Patients Doses Serious ADE
mg N N N Per patient Per dose
200 61 280 0 0.0% 0.0%
500 30 58 1 3.3% 1.7%
Table 5. Most frequently reported ADE, by treatment arm, in safety
evaluable patients
IV iron group Oral iron group
200 mg × 5 500mg × 2 325 mg tid × 56
ADE (N = 61) (N = 30) (N = 91)
Gastrointestinal 7 (11.5%) 1 (3.3%) 16 (17.6%)
Constipation 1 (1.6%) 8 (8.8%)
Diarrhea 3 (3.3%)
Nausea/vomiting 2 (3.3%) 5 (5.5%)
Dyspepsia 1 (1.6%) 1 (1.1%)
Dysgeusia 4 (6.6%) 1 (3.3%)
Headache 2 (3.3%)
Myalgia 2 (3.3%) 1 (3.3%)
Hypotension 2 (6.7%)
ADE, adverse drug event. One patient in each treatment group reported two
GI adverse events. Results given as number of patients (% column total). All
events except one episode of hypotension were judged nonserious. One patient
in each treatment group reported two gastrointestinal ADE.
significance. The second RCT, like the first, initiated iron
and epoetin alfa iron therapy simultaneously, thereby
confounding the effect of iron replacement with that of
erythropoietin replacement.
In the current trial, we sought to distinguish iron treat-
ment effects from ESA effects by randomizing patients
to iron treatment only after a six-month interval free of
IV iron and an eight-week interval without an ESA dose
change; in patients using ESA, we did not permit an ESA
dose change after randomization; and we did not initiate
ESA in patients not using ESA at randomization. Though
our trial period was relatively short, we found that the
erythropoietic response in the IV iron group was more
vigorous than that seen in the oral iron group.
We found several factors to be helpful in identifying
patients who particularly benefit from IV compared to
oral iron, including baseline ferritin, severity of anemia,
degree of remnant GFR, ongoing use of ESA, age, and
gender. In the oral iron treatment arm, patients with base-
line ferritin ≥100 ng/mL showed lower efficacy than did
those with ferritin levels <100 ng/mL, presumably be-
cause intestinal iron absorption declines as serum ferritin
increases [11, 12]. In the IV iron treatment arm, we saw no
relationship between efficacy and baseline ferritin, pre-
sumably because bioavailability of IV iron is independent
of intestinal iron absorption. Consistent with that reason-
ing, oral iron efficacy falls below that of IV iron especially
among patients with low Hb, low GFR, or lack of ESA
use. Since ESA administration boosts iron absorption in
erythropoietin deficient hemodialysis patients [13], and
anemia, a GFR below 40 mL/min, and lack of ESA each
indicate erythropoietin deficiency [14], the relative lack of
oral iron efficacy in each of these conditions may be due
to a lack of erythropoietin-stimulated iron absorption.
Not surprisingly, the single previous RCT that showed
IV iron to be unequivocally more effective than oral iron
included patients with the lowest GFR and most severe
anemia. Although the trial was small and included simul-
taneous initiation of ESA therapy, mean baseline creati-
nine clearance was <20 mL/min and mean baseline Hb
was <7 g/dL [5].
In hemodialysis patients, the iron status tests TSAT,
ferritin, and CHr are useful markers of iron deficiency, as
defined by response to a 1000 mg IV iron challenge [1].
In the current ND-CKD patients, however, these tests
proved unhelpful (Fig. 5). The poor clinical utility of iron
status tests in our study was likely related to relatively
small numbers of patients with test results in the low-
est range of each test, no patients with TSAT >25% or
ferritin >300 ng/mL and, most importantly, the weak cor-
relation between baseline indices of iron status and the
two indices of hemoglobinization response, CHr and
Hb (Fig. 6). Theoretically, increases in CHr should be
followed by increases in total Hb. Our finding that base-
line iron indices are more closely related to CHr than to
Hb, coupled with the observation that CHr remained
significantly elevated 56 days after IV iron administration
suggests that a 56-day study period may not capture the
full effect of IV iron on total blood Hb.
Increased quality of life is an important outcome of
anemia correction. No measurable improvement in qual-
ity of life was evidenced in either group, presumably be-
cause the observed increase in Hb was small.
Despite previous evidence in experimental animals
[15] and man [16] that IV iron administration may pro-
voke renal injury, we found renal function after IV iron
treatment to be well-preserved relative to that after oral
iron treatment. We conclude that the mild transient enzy-
muria and proteinuria seen after a single dose of 100 mg
IV iron [16] does not promote loss of renal function, even
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in CKD patients repeatedly exposed to 200 mg or 500 mg
doses.
Bioactive iron release from IV iron agents remains,
however, a clinically significant phenomenon that limits
the maximum single dose and rate of infusion of each
class of IV iron agent [17]. When too much IV iron is
given too fast, flank pain, cramps, and GI symptoms may
be seen. Hypotension, though usually self-limited, may be
serious. Our results confirm previous findings that 200 mg
iron sucrose administered IV over 2 to 5 minutes is well-
tolerated [4]. Hypotension after 500 mg iron sucrose in-
fused over 3.5 to 4 hours was limited to two females weigh-
ing less than ≤65 kg, evidence that plasma volume may
be an important determinant in mediating the effects of
labile or bioactive iron [18, 19].
The CKD patient with a Hb <11 g/dL and low iron
indices poses the compound clinical question, “What is
the likelihood that iron therapy will raise the Hb to or
above the Hb target (11 g/dL), is oral iron as effective as
IV iron, how soon is the response to iron complete, and
how long does the iron treatment effect last?” Our results
suggest that within eight weeks after initiating therapy,
about 43% of patients will reach target Hb with thrice-
daily oral iron and about 60% will reach target Hb after
a 1000 mg IV iron challenge. If the test of efficacy is a
≥1 g/dL rise in Hb after iron therapy, lower response rates
should be expected. However, if the patient is male, ESA
therapy is present, the Hb is below 10 g/dL, the GFR is
below 45 m/min/1.73m2, or the age is over 65, the fraction
showing a 1 g/dL Hb rise after IV iron without starting
ESA or increasing ESA doses may equal or exceed 50%
(Table 3).
Our study does not exclude the possibility that greater
efficacy can be achieved either by increasing the IV iron
dose or by extending the period of oral iron supplemen-
tation. Among patients given 1000 mg iron sucrose in
divided IV doses, we found that the mean posttreatment
TSAT was 25.1% and that 16 out of 79 patients achieved
a mean TSAT ≥30%. Conceivably, since iron efficacy de-
pends on delivering adequate iron for erythropoiesis and
adequacy of iron delivery depends, in turn, on the level of
TSAT, adjusting IV iron doses to achieve a target thresh-
old TSAT (for example, ≥30%), rather than limiting the
IV iron dose to 1000 mg, may lead to a greater increase
in Hb than we observed.
We suspect that, just as IV iron efficacy may be con-
strained by underdosing, oral iron efficacy may be limited
by short treatment duration. Among patients receiving
oral iron, we found that the peak Hb response occurs
early, well before completion of a 56-day study period.
However, the continued albeit very slow rise of ferritin
over 56 days among oral iron treated patients leaves open
the possibility that longer periods of oral iron therapy
could lead to later increases in Hb. On the other hand, a
longer treatment period might engender greater nonad-
herence with oral therapy, a significant problem even in
the current 56-day trial.
CONCLUSION
The final decision to choose between IV and oral iron
will depend on how the clinician and patient weigh issues
of efficacy, safety, tolerability, convenience, compliance,
and cost. In managing CKD-associated anemia, the effec-
tive cost of iron therapy includes not only the cost of the
iron agent but also the saved cost, if any, of lower ESA
doses. Using a fixed-ESA-dose study design, we have
shown IV iron sucrose therapy to be safe, well-tolerated,
and more effective than oral iron treatment. Further stud-
ies exploring higher IV iron doses, longer treatment inter-
vals, and flexible ESA dosing will be needed to compare
the efficacy of IV versus oral iron in minimizing ESA
needs.
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